Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer

Biochemical and Biophysical Research Communications

Volumn 447, Issue 3, 2014, Pages 490-495

  Wairagu, Peninah M ^a   Park, Kwang Hwa ^a   Kim, Jihye ^a   Choi, Jong Whan ^a   Kim, Hyun Won ^a   Yeh, Byung Il ^a   Jung, Soon Hee ^a   Yong, Suk Joong ^a   Jeong, Yangsik ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Combinational therapy; Lung cancer; LXR; PPAR ; Tyrosine kinase inhibitors

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CYCLIN B; CYCLIN D1; GEFITINIB; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; LUNG CANCER; LUNG CANCER CELL LINE; METASTASIS; PRIORITY JOURNAL;

COMBINATIONAL THERAPY; LUNG CANCER; LXR; PPARΓ; TYROSINE KINASE INHIBITORS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLIN B; CYCLIN D1; HUMANS; HYDROCARBONS, FLUORINATED; INDOLES; LUNG NEOPLASMS; ORPHAN NUCLEAR RECEPTORS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES; SULFONES;

EID: 84900296664     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.018     Document Type: Article

References (26)

1. Jeong Y., Xie Y., Lee W., Bookout A.L., Girard L., Raso G., Behrens C., Wistuba I.I., Gadzar A.F., Minna J.D., Mangelsdorf D.J. Research resource: diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol. Endocrinol. 2012, 26:1443-1454.
2. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
3. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., Loda M., Weber G., Mark E.J., Lander E.S., Wong W., Johnson B.E., Golub T.R., Sugarbaker D.J., Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 2001, 98:13790-13795.
4. West L., Vidwans S.J., Campbell N.P., Shrager J., Simon G.R., Bueno R., Dennis P.A., Otterson G.A., Salgia R. A novel classification of lung cancer into molecular subtypes. PLoS ONE 2012, 7:e31906.
5. Bronte G., Rizzo S., La Paglia L., Adamo V., Siragusa S., Ficorella C., Santini D., Bazan V., Colucci G., Gebbia N., Russo A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 2010, 36(Suppl. 3):S21-S29.
6. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
7. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., Seymour L. National Cancer Institute of Canada Clinical Trials. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353:123-132.
8. Kunz M. Oncogenes in melanoma: An update. Eur. J. Cell Biol. 2013.
9. Liu S., Knapp S., Ahmed A.A. The structural basis of PI3K cancer mutations: from mechanism to therapy. Cancer Res. 2014, 74:641-646.
10. Gerber D.E. Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician 2008, 77:311-319.
11. Vignot S., Faivre S., Aguirre D., Raymond E. MTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16:525-537.
12. Lavi O., Greene J.M., Levy D., Gottesman M.M. The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res. 2013.
13. Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., Chodon T., Guo R., Johnson D.B., Dahlman K.B., Kelley M.C., Kefford R.F., Chmielowski B., Glaspy J.A., Sosman J.A., van Baren N., Long G.V., Ribas A., Lo R.S. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2013.
14. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., Lindeman N.I., Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M., Iafrate A.J., Lee C., Christensen J.G., Engelman J.A., Janne P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
15. Bock C., Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat. Rev. Cancer 2012, 12:494-501.
16. Jeong Y., Mangelsdorf D.J. Nuclear receptor regulation of stemness and stem cell differentiation. Exp. Mol. Med. 2009, 41:525-537.
17. Hong C., Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 2008, 18:461-467.
18. Rondini E.A., Harvey A.E., Steibel J.P., Hursting S.D., Fenton J.I. Energy balance modulates colon tumor growth: interactive roles of insulin and estrogen. Mol. Carcinog. 2011, 50:370-382.
19. Jeong Y., Xie Y., Xiao G., Behrens C., Girard L., Wistuba I.I., Minna J.D., Mangelsdorf D.J. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010, 7:e1000378.
20. Bookout A.L., Cummins C.L., Mangelsdorf D.J., Pesola J.M., Kramer M.F. High-throughput real-time quantitative reverse transcription PCR. Curr. Protoc. Mol. Biol. 2006, Chapter 15. Unit 15 18.
21. Bock C., Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat. Rev. Cancer 2012, 12:494-501.
22. Jain L., Abraham S., Shord S.S. The interactions of anti-cancer drugs approved in the last decade in the United States with membrane transporters. Anticancer Agents Med. Chem. 2010, 10:601-616.
23. Grommes C., Landreth G., Heneka M. Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists. Lancet Oncol. 2004, 5:419-429.
24. Zang C., Liu H., Posch M.G., Waechter M., Facklam M., Fenner M.H., Ruthardt M., Possinger K., Phillip Koeffler H., Elstner E. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk. Res. 2004, 28:387-397.
25. Chuu C.P., Hiipakka R.A., Kokontis J.M., Fukuchi J., Chen R.Y., Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 2006, 66:6482-6486.
26. Guo D., Reinitz F., Youssef M., Hong C., Nathanson D., Akhavan D., Kuga D., Amzajerdi A.N., Soto H., Zhu S., Babic I., Tanaka K., Dang J., Iwanami A., Gini B., Dejesus J., Lisiero D.D., Huang T.T., Prins R.M., Wen P.Y., Robins H.I., Prados M.D., Deangelis L.M., Mellinghoff I.K., Mehta M.P., James C.D., Chakravarti A., Cloughesy T.F., Tontonoz P., Mischel P.S. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011, 1:442-456.